(MTNB) Matinas BioPharma Holdings, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MTNB) Matinas BioPharma Holdings, Inc. Complete Analysis Pack
See the Bigger Picture
This Matinas BioPharma Holdings, Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing strategy, distribution channels, and promotional approaches to show how it competes in biotech/pharma markets; the page contains a real preview/sample of the analysis so you can evaluate style and content—purchase the full version to get the complete ready-to-use report.
Product
LNC platform technology
Matinas BioPharma Holdings, Inc. centers its product mix on the LNC platform technology, one engine built to carry 6 payload classes: small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. In 2025 filings, this platform remained the basis of the company’s pipeline and partnering model, so its value lies in reach across multiple drug types, not one asset. That breadth can support faster deal flow and lower single-product risk.
LYPDISO omega-3 candidate
LYPDISO is Matinas BioPharma Holdings, Inc.'s proprietary prescription-grade omega-3 free fatty acid program and the company’s lead experimental asset. It targets cardiovascular and metabolic disorders, two large markets tied to elevated triglycerides, insulin resistance, and obesity. As a development-stage asset, its value still depends on clinical proof, regulatory progress, and partner interest.
MAT2203 oral amphotericin B
MAT2203 is Matinas BioPharma Holdings, Inc.'s oral amphotericin B in Phase II for preventing invasive fungal infections in immunosuppressed patients. The oral route could improve patient use versus IV amphotericin B, which is limited by infusion burden and toxicity. Matinas BioPharma Holdings, Inc. has not reported 2026 product sales for MAT2203 yet, so value still depends on trial readouts and later partnering.
MAT2501 oral amikacin
MAT2501 is Matinas BioPharma Holdings, Inc.'s oral amikacin program for hard-to-treat resistant infections. It has completed Phase I, which supports early human safety and exposure data for an oral delivery approach to a drug usually given intravenously.
The target set includes non-tuberculous mycobacterium and multidrug-resistant gram-negative pathogens, both high-need markets with limited oral options. For investors, the key point is that MAT2501 is still a clinical-stage asset, so value is tied to later efficacy data and partner interest, not current product sales.
- Oral amikacin candidate
- Phase I completed
- Targets MDR bacteria
- Clinical-stage, no sales yet
Broad anti-infective pipeline
Matinas BioPharma Holdings, Inc.'s broad anti-infective pipeline spans antivirals, antifungals, antibacterials, and biologic delivery applications, so it is not tied to one drug class. The company is also developing oral and other differentiated formulations, which can widen the addressable market and improve use across multiple infection settings.
- Four anti-infective areas
- Oral and differentiated formats
- Broader reach than one class
- Supports biologic delivery use
That mix gives Matinas BioPharma Holdings, Inc. more ways to build value if one program moves slower, because success can come from several product paths. The strategy also fits a broader platform model, where one delivery approach can serve more than one therapy type.
Platform-Led Pipeline, No Product Revenue Yet
Matinas BioPharma Holdings, Inc.'s product mix is still platform-led: LNC can carry small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides, so one delivery system can support multiple drug classes. In 2025 filings, the company still had no reported product revenue from these pipeline assets.
| Asset | Stage | Key point |
|---|---|---|
| LNC | Platform | 6 payload classes |
| MAT2203 | Phase II | Oral amphotericin B |
| MAT2501 | Phase I | Oral amikacin |
What is included in the product
Detailed Word Document
A concise, company-specific 4P analysis of Matinas BioPharma Holdings, Inc.’s product, pricing, place, and promotion strategy.
Editable Excel File
Condenses Matinas BioPharma’s 4Ps into a quick, decision-ready snapshot for faster alignment and planning.
Reference Sources
Provides a concise, traceable bibliography of primary industry reports, regulatory filings, and peer-reviewed studies to speed due diligence on Matinas BioPharma.
Place
Bedminster New Jersey HQ
Matinas BioPharma Holdings, Inc. is headquartered in Bedminster, New Jersey, and that site is its main operating base. Corporate functions are centralized there, so key decisions, administration, and coordination for the business flow through one hub. For the 4P's mix, this location supports tighter control, faster internal communication, and a leaner operating setup.
Clinical development channels
Matinas BioPharma Holdings, Inc. reaches patients through clinical trial networks, not retail channels. Its assets are tested in investigator-led and sponsor-run studies, so access depends on research sites, IRB approval, and FDA pathways. With no approved commercial product, the channel is still tied to clinical enrollment and regulatory milestones.
Phase II and Phase I sites
Matinas BioPharma Holdings, Inc. currently “places” its lead assets in clinical trial sites, not retail channels: MAT2203 is in Phase II testing, while MAT2501 has completed Phase I. That means 2 active clinical development stages define where the Company’s products are present today. This site-based model keeps the pipeline close to investigators, patients, and trial data.
NIAID collaboration channel
Matinas BioPharma Holdings, Inc. uses the NIAID collaboration channel to plug into the National Institute of Allergy and Infectious Diseases research network. The link supports remdesivir-related work and gives Matinas access to U.S. government research infrastructure, which matters in infectious-disease programs where NIAID funded $6.6B in FY2024.
- Supports remdesivir-related research
- Connects to NIAID infrastructure
- Extends public-sector reach
Genentech feasibility collaboration
Matinas BioPharma Holdings, Inc. keeps a feasibility collaboration with Genentech, Inc. focused on new oral drug formulations, giving the company a second partner-led path to development and possible commercialization. This kind of pharma tie-up matters because oral delivery can improve patient use and broaden product reach.
- Partner route lowers solo R&D burden
- Oral formulations can expand market access
- Feasibility work supports later licensing
Matinas BioPharma’s Lean Pipeline Runs from Bedminster to Trial Sites
Matinas BioPharma Holdings, Inc. places its pipeline mainly in Bedminster, New Jersey, and in research sites tied to its trial and partner networks. That model keeps operations lean: 1 HQ hub, 2 active development programs, and access shaped by clinical milestones, not retail distribution.
| Place driver | Current setup |
|---|---|
| HQ | Bedminster, New Jersey |
| Clinical access | Trial sites and partners |
| Active programs | MAT2203 Phase II, MAT2501 Phase I done |
Get Your Copy
Matinas BioPharma Holdings, Inc. Reference Sources
The preview shown here is the actual Matinas BioPharma 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises.
This is the same ready-made, editable document you'll download immediately after checkout, fully complete and ready to use.
Promotion
Clinical trial updates
Promotion relies on clinical trial updates to keep the pipeline visible, with Phase II and Phase I milestones as the main proof points. For a development-stage Company like Matinas BioPharma Holdings, Inc., these updates are the core investor and partner message because they signal data progress, not sales. Clinicians also watch them for safety, efficacy, and dose-readout detail.
NIAID partnership visibility
NIAID partnership visibility adds real scientific weight to Matinas BioPharma Holdings, Inc., because NIH spent $47.0 billion in FY2024 and NIAID-backed work carries strong external credibility. The remdesivir link shows the platform can support more than one internal program, which helps signal broader relevance to partners and investors. Government research participation can also lift attention fast when a company is still building market trust.
Genentech collaboration news
Genentech feasibility work is a strong promotional asset for Matinas BioPharma Holdings, Inc. It gives the LNC platform validation from one of the world’s largest biopharma groups, Roche’s Genentech, which can lift trust with partners and investors. In 2025, that kind of third-party signal matters more than claims alone, because it helps the platform stand out in a crowded delivery-tech market.
Platform differentiation
Matinas BioPharma Holdings, Inc. sells LNC as a platform, not a one-drug story: it says the tech improves oral delivery and can fit more therapies. That matters because a platform can support multiple programs and lower single-asset risk.
LNC = core brand message
Focus: oral delivery plus broader use
Positions the company as platform-led
Investor and scientific communication
As a clinical-stage Company, Matinas BioPharma Holdings, Inc. uses investor decks, SEC filings, and scientific updates as its main promotion tools before any product launch. In 2025, it still had no commercial product revenue, so pipeline progress, trial data, and partnership news matter most for market visibility. That makes investor and scientific communication a core part of its 4P promotion mix.
- Pre-launch promotion depends on disclosures
- Trial updates drive investor interest
- Partnership news supports credibility
- No product sales in 2025
Matinas Leans on Clinical and NIH-Backed Proof, Not Sales
Promotion for Matinas BioPharma Holdings, Inc. is mostly clinical and partner driven, not sales driven. In 2025, it had no commercial product revenue, so Phase I and Phase II updates, NIH-backed work, and Genentech feasibility data were the main proof points. The NIAID link matters because NIH spent $47.0 billion in FY2024.
| Signal | Value |
|---|---|
| Commercial revenue | 0 in 2025 |
| NIH FY2024 spend | $47.0 billion |
| Main promo tool | Trial and partner updates |
Price
No marketed product price
Matinas BioPharma Holdings, Inc. has no approved commercial products, so there is no retail list price for its lead assets. Pricing is still pre-commercial and will only be set after regulatory approval and launch. As a result, current value is driven by R&D progress and cash position, not product sales.
Clinical-stage value pricing
Matinas BioPharma Holdings, Inc. is priced as a clinical-stage biotech, so value comes from pipeline probability, not current sales. Phase I and Phase II assets are judged by the chance of approval and future cash flows, which is standard for development-stage biopharma. If trial data improves, the valuation can re-rate fast; if it disappoints, it can fall just as quickly.
Partner-based economics
Matinas BioPharma Holdings, Inc. uses a partnership-based pricing model, so value is tied less to direct product sales and more to collaboration terms. Work with NIAID and Genentech can bring research support, milestone payments, and possible licensing income, which lowers the need to price products for end-market demand. This fits a platform-style biotech model where economics depend on deal terms, not just unit price.
Specialty-drug premium potential
If Matinas BioPharma Holdings, Inc. gets approval, its oral antifungal and anti-infective drugs would likely sit in the specialty-drug tier, where prices are higher because unmet need is high and alternatives are limited.
Exact pricing is not disclosed. In this market, orphan and specialty medicines often clear four- to five-figure annual treatment costs when they show clear clinical value.
- Specialty therapy pricing power is high
- Oral anti-infectives can support premiums
- Matinas BioPharma Holdings, Inc. has no public price
Cost-avoidance value proposition
Matinas BioPharma Holdings, Inc.'s oral delivery model can cut the burdens tied to infusion or injection care, where site-of-care fees, nursing time, and patient travel add up fast. For payers, that supports a price case built on lower total treatment cost, not just drug cost.
That matters in reimbursement talks because oral therapy can reduce chair time and home-visit needs while improving convenience. Price would likely be set to reflect that clinical and economic value, especially if it helps avoid part of the more than $1,000 in typical U.S. infusion-related facility and administration costs per visit.
- Less admin burden
- Lower care-site costs
- Stronger payer case
- Price tracks value
Matinas: No Price Yet, But Oral Delivery Could Support Premium Pricing
Price is still pre-commercial for Matinas BioPharma Holdings, Inc., because it has no approved products and no public list price. Any future price will likely be set after approval, using specialty-drug economics, where payers judge total value, not just unit cost. Oral delivery could support a premium if it lowers infusion and administration costs.
| Item | Price signal |
|---|---|
| Commercial status | No approved products |
| Current pricing | Not disclosed |
| Likely future tier | Specialty drug |
| Value driver | Lower care-site cost |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.